




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :		A1	(11) International Publication Number:	WO 00/24897
C12N 15/13, 5/10, 15/62, G01N 33/53, A61K 45/00, 9/48			(43) International Publication Date:	4 May 2000 (04.05.00)
(21) International Application Number:		PCT/US99/24630	(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P. C., One Financial Center, Boston, MA 02111 (US).	
(22) International Filing Date:		21 October 1999 (21.10.99)		
(30) Priority Data:		26 October 1998 (26.10.98) US	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application		US 09/178,869 (CIP) Filed on 26 October 1998 (26.10.98)		
(71) Applicant (for all designated States except US): CYTOTHERAPEUTICS, INC. [US/US]; 701 George Washington Highway, Lincoln, RI 02865 (US).				
(72) Inventors; and				
(75) Inventors/Applicants (for US only): TAO, Weng [US/US]; 6 Rivet Drive, Lincoln, RI 02865 (US). WONG, Shou [US/US]; 2970 Mendon Road, Chestnut Villa 97, Cumberland, RI 02864 (US). HICKEY, William, F. [US/US]; 26 Recordridge Lane, Lyme, NH 03768 (US). HAMMANG, Joseph, P. [US/US]; 3 Prospect Street, Barrington, RI 02806 (US). BAETGE, E., Edward [US/CH]; 82, rue du Centre, CH-1025 St-Sulpice (CH).				

(54) Title: CELL SURFACE MOLECULE-INDUCED MACROPHAGE ACTIVATION



## (57) Abstract

This invention provides cells containing recombinant polynucleotides coding for cell surface molecules that, when expressed in the cell, result in rejection of the cell by the host immune system. The invention also provides methods of using such cells, and capsules for delivery of biologically active molecules to a patient.